Epkinly was first approved as a monotherapy by the FDA in 2023 for adults with relapsed or refractory DLBCL.
PVR demonstrated superiority versus VR in the ITT analysis population; benefits consistent across prespecified subgroups.
A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...
Surge Copper (TSXV: SURG) says it is advancing work towards a pre-feasibility study (PFS) on its Berg project in west-central British Columbia, with completion expected during the first half of next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results